论文部分内容阅读
目的:研究盐酸替罗非班在ST段抬高急性心肌梗死(STEMI)治疗的临床应用疗效。方法:选取南通市通州区人民医院和上海市第一人民医院共收治的80例接受急诊经皮冠状动脉介入治疗(PCI)的STEMI患者作为观察对象,随机分为对照组与治疗组。对照组给予肝素、阿司匹林、氯吡格雷治疗,治疗组则在对照组的基础上联合实施盐酸替罗非班治疗。记录2组患者的手术一般情况,统计2组患者在住院期间与住院之后心脏不良事件(MACE)的发生率。结果:治疗组术后的临床疗效明显优于对照组(P<0.05),治疗组的MACE发生率大于对照组。结论:针对STEMI行PCI治疗的患者,对其采用盐酸替罗非班治疗,能够显著提高患者的临床疗效,对其治疗过程中出现的不良反应加以监测与采取相应的治疗,症状均可缓解。
Objective: To study the clinical effect of tirofiban hydrochloride in the treatment of ST-elevation acute myocardial infarction (STEMI). Methods: Totally 80 STEMI patients undergoing percutaneous coronary intervention (PCI) in Tongzhou District People’s Hospital of Nantong and Shanghai First People’s Hospital were randomly divided into control group and treatment group. The control group was given heparin, aspirin and clopidogrel. The treatment group was treated with tirofiban hydrochloride on the basis of the control group. The general operation of the two groups of patients was recorded, and the incidence of cardiac adverse events (MACE) between the two groups during hospitalization and after hospitalization was calculated. Results: The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). The incidence of MACE in the treatment group was greater than that of the control group. Conclusions: Tirofiban Hydrochloride for patients with STEMI undergoing PCI can significantly improve the clinical efficacy, monitor the adverse reactions during the course of treatment and take corresponding treatment, and the symptoms can be relieved.